Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: Pooled data from two prospective randomised controlled trials

Authors

George R Thompson 3rd, University of California, Davis
Marin Kollef, Washington University School of Medicine in St. Louis
et al.

Journal

Lancet Infectious Diseases

Publication Date

3-1-2024

Volume

24

Issue

3

First Page

319

Last Page

328

Document Type

Open Access Publication

DOI

10.1016/S1473-3099(23)00551-0

Rights and Permissions

Thompson GR 3rd, Soriano A, Honore PM, Bassetti M, Cornely OA, Kollef M, Kullberg BJ, Pullman J, Hites M, Fortún J, Horcajada JP, Kotanidou A, Das AF, Sandison T, Aram JA, Vazquez JA, Pappas PG. Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials. Lancet Infect Dis. 2024 Mar;24(3):319-328. doi: 10.1016/S1473-3099(23)00551-0. © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Recommended Citation

Thompson, George R 3rd; Kollef, Marin; and et al., "Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: Pooled data from two prospective randomised controlled trials." Lancet Infectious Diseases. 24, 3. 319 - 328. (2024).
https://digitalcommons.wustl.edu/oa_4/5327

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.